CRSPNEUTRAL

EV/EBITDA

-8.7x

Higher than 2% of Healthcare sector peers

Updated 1078h ago

Sector Performance

2th percentile

CRSP

-8.7x

Sector Median

12.8x

Sector Avg

15.6x

📊

Deep Analysis

The EV/EBITDA ratio compares a company's enterprise value to its earnings before interest, taxes, depreciation, and amortization.

A negative value of -8.7x means CRISPR Therapeutics has negative EBITDA — it is not yet profitable from its operations. Among healthcare sector peers, the median EV/EBITDA is 13.4x, placing CRSP in the 5th percentile, far below the typical positive multiple. No year-over-year or quarter-over-quarter change data is available, so the trend is not observable. The combination of a negative EV/EBITDA with no trend history implies high uncertainty; such a metric is common for early-stage biotech firms with no revenue, but it offers no clear signal on improving or worsening profitability. This metric supports the overall NEUTRAL verdict because the negative valuation ratio neither confirms a buying opportunity nor definitively flags overvaluation — it reflects the stock’s pre-commercial stage, consistent with a balanced view.

Frequently Asked Questions

What does the EV/EBITDA tell investors about CRSP?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does CRSP's EV/EBITDA compare to its sector?

CRSP's EV/EBITDA of -8.7x compares to a Healthcare sector median of 12.8x, placing it in the 2th percentile.

Who are CRSP's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: BDX (12.2x), GSK (10.2x), CPRX (10.1x), ZBH (9.7x), BAX (9.4x).

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.